Vitor Hugo Luna Rocha de Almeida
Instituição:
Universidade Federal do Rio de Janeiro
Centro:
Centro de Ciências da Saúde
Unidade:
Instituto de Bioquímica Médica
Departamento:
Direção Adjunta de Gestão Administrativa/IBqM
Formação:
-
Universidade Federal do Rio de Janeiro
| Pós-Doutorado | 2018 - Agora
-
Universidade Federal do Rio de Janeiro
Química Biológica | Doutorado | 2013 - 2018
-
Instituto Nacional de Câncer
ONCOLOGIA | Mestrado | 2011 - 2013
-
Instituto Nacional de Câncer
Oncologia | Aperfeiçoamento | 2010 - 2011
-
Universidade Federal do Rio de Janeiro
Farmácia | Graduação | 2006 - 2010
-
Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
Biotecnologia | Ensino Profissional de nível técnico | 2003 - 2005
-
Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
| Ensino Médio (2o grau) | 2003 - 2005
Laboratórios:
Nenhum laboratório cadastrado
Nuvens de Palavras:
Artigos:
(94.74% artigos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| TF/PAR2 Signaling Axis Supports the Protumor Effect of Neutrophil Extracellular Traps (NETs) on Human Breast Cancer Cells | 10.3390/cancers16010005 | 2024 |
| Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between αv and β1 Integrins, E-Cadherin and HER-2 | 10.3390/ijms231710194 | 2022 |
| Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications | 10.1590/1414-431x202010754 | 2021 |
| Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial-Mesenchymal Transition | 10.3390/cancers12061542 | 2020 |
| Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer | 10.3389/fonc.2020.557280 | 2020 |
| Pisum sativum Defensin 1 Eradicates Mouse Metastatic Lung Nodules from B16F10 Melanoma Cells | 10.3390/ijms21082662 | 2020 |
| Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis | 10.3390/cells8070716 | 2019 |
| Tissue factor mediates microvesicles shedding from MDA-MB-231 breast cancer cells | 10.1016/j.bbrc.2018.05.136 | 2018 |
| Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer | 10.18632/oncotarget.25748 | 2018 |
| Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells | 10.1016/j.bbrc.2018.08.169 | 2018 |
| Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia | 10.1016/j.exphem.2018.07.008 | 2018 |
| Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms | 10.1016/j.thromres.2017.09.019 | 2017 |
| Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer | 10.1590/1414-431x20176822 | 2017 |
| TR47, a PAR1-based peptide, inhibits melanoma cell migration in vitro and metastasis in vivo | 10.1016/j.bbrc.2017.11.174 | 2017 |
| Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma? | 10.21037/tcr.2016.11.30 | 2016 |
| Novos fármacos com alvo molecular específico em oncologia | 2011 | |
| Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab | 10.1186/1476-4598-10-151 | 2011 |
| Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway | 10.1016/j.ejca.2008.12.012 | 2009 |
| Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells | 10.1038/sj.bjc.6605216 | 2009 |
Eventos:
(5.56% eventos com DOI)
| Titulo | DOI | Ano |
|---|---|---|
| DUAL EFFECT OF NEUTROPHIL EXTRACELLULAR TRAPS (NETs) ON CERVICAL CANCER CELLS | 2023 | |
| NEUTROPHIL EXTRACELLULAR TRAPS (NETS) DRIVE A CHEMORESISTANT PHENOTYPE IN HUMAN BREAST CANCER CELLS THROUGH PI3K/AKT/NF-kB PATHWAY | 2023 | |
| EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND PROSTAGLANDIN E2 (PGE2): A LINK BETWEEN INFLAMMATION AND CERVICAL CANCER | 2023 | |
| NEUTROPHIL EXTRACELLULAR TRAPS (NETS) DRIVE AN ANTIAPOPTOTIC PHENOTYPE IN HUMAN BREAST CANCER CELLS: IMPLICATIONS FOR CHEMORESISTANCE | 2022 | |
| INFLAMMASOME ACTIVATION BY NEUTROPHIL EXTRACELLULAR TRAPS (NETs) IN HUMAN BREAST CANCER MODELS | 2022 | |
| NEUTROPHIL EXTRACELLULAR TRAPS (NETS) DRIVE A CHEMORESISTANT PHENOTYPE IN HUMAN BREAST CANCER CELLS THROUGH PI3K/AKT/NF-kB PATHWAY | 2022 | |
| CROSSTALK BETWEEN EPIDERMAL GROWTH FACTOR RECECPTOR (EGFR) AND PROSTAGLANDIN E2 (PGE2): A POSSIBLE LINK BETWEEN CERVICAL CANCER AND INFLAMMATION? | 2022 | |
| PRO-TUMORIGENIC EFFECTS OF NEUTROPHIL EXTRACELLULAR TRAPS (NETS) IN CASKI CERVICAL CANCER CELLS | 2022 | |
| ROLE OF INTERLEUKINE 8 (IL-8) IN TISSUE FACTOR (TF)-MEDIATED PROGRESSION OF HUMAN BREAST CARCINOMA | 2021 | |
| EVIDENCE FOR INFLAMMASOME ACTIVATION IN BREAST CANCER CELLS BY NEUTROPHIL EXTRACELLULAR TRAPS (NETs) | 2021 | |
| Neutrophil Extracellular Traps (Nets) Increase the Pro-Tumoral Properties of the Human Breast Cancer Cell Line, MCF7 | 2020 | |
| NEUTROPHIL EXTRACELLULAR TRAPS (NETS) INDUCE PROCOAGULANT PHENOTYPE IN HUMAN BREAST CANCER CELLS | 2020 | |
| INTERPLAY BETWEEN EGFR AND THE PLATELET-ACTIVATING FACTOR (PAF)/PAF RECEPTOR SIGNALING AXIS MEDIATES AGGRESSIVE BEHAVIOR OF CERVICAL CANCER | 2020 | |
| Neutrophil Extracellular Traps (NETs) increase the pro-tumoral properties of the human breast cancer MCF-7 cell line | 2019 | |
| Role of Tissue Factor (TF) in IL-8-mediated progression of human breast carcinoma | 2019 | |
| Analysis of the crosstalk between EGF receptor and the PAF signaling pathway in cervical cancer | 2019 | |
| Neutrophil Extracellular Traps (NETs) increase the pro-tumoral properties of the human breast cancer MCF-7 cell line | 2019 | |
| Estabelecimento de um modelo in vitro de câncer de mama para avaliação do receptor ativado por protease como alvo terapêutico | 10.35259/isi.sact.2018_27296 | 2018 |
| Positive crosstalk between EGF receptor and clotting proteins mediates resistance to cisplatin and poor survival in cervical cancer | 2018 | |
| Effects of non-canonical activation of protease-activated receptor 1 (PAR1) in melanoma cell lines | 2018 | |
| Crosstalk between Epidermal Growth Factor Receptor (EGFR) and TF/FVIIa/PAR -2 pathway mediates chemotherapy resistance in cervical cancer | 10.3252/pso.eu.ISTH2017.2017 | 2017 |
| CROSSTALK BETWEEN EPIDERMAL GROWTH FACTOR RECECPTOR (EGFR) AND TF/FVIIa/PAR2 PATHWAY MEDIATES CHEMOTHERAPY RESISTANCE IN CERVICAL CANCER | 2017 | |
| Tumor-derived microvesicles mediate transfer of tissue-factor procoagulant activity | 2016 | |
| Platelet activation and aggregation by breast cancer exosomes | 2015 | |
| On the role of breast cancer exosomes in platelet activation and aggregation | 2015 | |
| Estudo do papel de exossomos provenientes de linhagens de carcinoma mamário humano na biologia plaquetária e coagulação sanguínea | 2014 | |
| Identificação de marcadores de radiorresistência no câncer cervical: pesquisa baseada em modelo in vitro e em estudo clínico de fase 0 | 2013 | |
| Correlation between XIAP, pAkt, and ATP7A expression and cisplatin resistance in non-small cell lung cancer | 2012 | |
| Correlation between ATP7A, XIAP and p-AKT expression and cisplatin resistance in non-small cell lung cancer | 2011 | |
| Inibição da via PI3K/Akt é um fator determinante para reverter a resistência ao matuzumabe in vitro | 2011 | |
| The effectiveness of the combination of cisplatin, radiation therapy and cetuximab on squamous cell carcinoma cell lines is independent of EGFR status | 2008 | |
| Combination of cetuximab with cisplatin and radiation therapy may have useful applications for the treatment of cervical cancer | 2008 | |
| Efeitos do anticorpo monoclonal matuzumab (EMD 72000) na radio e quimiossensibilização de linhagens de câncer ginecológico | 2008 | |
| A new therapeutic strategy for the treatment of cervical cancer: a study based on human cell lines | 2007 | |
| Differences in activity between matuzumab and cetuximab in A431 cells may rely on MAPK cascade inhibition | 2007 | |
| Differences in activity between Matuzumab and Cetuximab in A431 cells may rely on MAPK cascade inhibition | 2007 |